Immutep announces first patient dosed in TACTI-004 Phase III trial

Immutep (IMMP) announces the first patient has been successfully dosed in the Company’s pivotal TACTI-004 Phase III trial. TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD’s anti-PD-1 therapy KEYTRUDA and chemotherapy as first line treatment for patients with advanced or metastatic non-small cell lung cancer, 1L NSCLC. First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep. Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites